Intech Investment Management LLC Lowers Stake in Humana Inc. (NYSE:HUM)

Intech Investment Management LLC cut its holdings in Humana Inc. (NYSE:HUM) by 56.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,903 shares of the insurance provider’s stock after selling 81,723 shares during the quarter. Intech Investment Management LLC owned approximately 0.05% of Humana worth $23,130,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Pzena Investment Management LLC grew its holdings in Humana by 538.7% during the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after acquiring an additional 1,955,375 shares in the last quarter. Davis Selected Advisers grew its holdings in Humana by 16.1% during the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after acquiring an additional 321,233 shares in the last quarter. Sanders Capital LLC bought a new position in Humana during the 4th quarter worth about $489,300,000. Ontario Teachers Pension Plan Board grew its holdings in Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after acquiring an additional 1,050,459 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Humana by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,248 shares of the insurance provider’s stock worth $380,368,000 after acquiring an additional 20,891 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

Humana stock opened at $312.00 on Friday. The company’s fifty day moving average price is $359.14 and its 200 day moving average price is $345.90. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The stock has a market capitalization of $37.60 billion, a P/E ratio of 19.43, a P/E/G ratio of 2.56 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the company earned $8.94 EPS. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.13%. Humana’s dividend payout ratio is presently 22.04%.

Analysts Set New Price Targets

HUM has been the subject of several analyst reports. Oppenheimer increased their price target on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Morgan Stanley initiated coverage on shares of Humana in a research report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price target for the company. Royal Bank of Canada increased their price target on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Robert W. Baird began coverage on shares of Humana in a research report on Thursday, May 30th. They issued a “neutral” rating and a $374.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.